title: HLA-identical sibling allogeneic peripheral blood stem cell transplantation with reduced intensity conditioning compared to autologous peripheral blood stem cell transplantation for elderly patients with de novo acute myeloid leukemia.
abstract: We conducted a retrospective registry-based analysis to compare the outcome of 361 allogeneic human leukocyte antigen (HLA)-identical peripheral blood stem cell transplants (PBSCT) with reduced intensity conditioning (RIC) to that of 1369 autologous (auto) PBSCT in patients aged 50 years or older with de novo acute myeloid leukemia (AML), performed from 1997 until 2003 and reported to the European Group for Blood and Marrow Transplantation. Median age was 58 and 57 years in the RIC and auto groups, respectively. RIC patients had more advanced disease at the time of transplant. At a median follow-up of 24 months for RIC and 16 months for auto, multivariate analysis showed a lower risk for relapse (RR 0.77, P=0.013) without increased non-relapse mortality (NRM) in RIC patients (RR 1.26, P=0.28). Moreover, leukemia-free survival (RR 1.22, P=0.02) and overall survival (OS) (RR 1.32, P=0.005) were superior in the RIC group. In patients in 1st (CR), fewer relapses were counterbalanced by significantly increased NRM. Therefore, there was no survival advantage in this subgroup. In patients in 2nd or subsequent CR, LFS and OS were superior in the RIC group. RIC transplants show encouraging results in this older patient population with de novo AML.
authors.affiliation: Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
authors.forename: A-L
authors.initials: AL
authors.lastname: Herr
authors.forename: M
authors.initials: M
authors.lastname: Labopin
authors.forename: D
authors.initials: D
authors.lastname: Blaise
authors.forename: N
authors.initials: N
authors.lastname: Milpied
authors.forename: M
authors.initials: M
authors.lastname: Potter
authors.forename: M
authors.initials: M
authors.lastname: Michallet
authors.forename: W
authors.initials: W
authors.lastname: Heit
authors.forename: F
authors.initials: F
authors.lastname: Ferrara
authors.forename: J
authors.initials: J
authors.lastname: Esteve
authors.forename: W
authors.initials: W
authors.lastname: Arcese
authors.forename: G
authors.initials: G
authors.lastname: Ehninger
authors.forename: J M
authors.initials: JM
authors.lastname: Rowe
authors.forename: G
authors.initials: G
authors.lastname: Kobbe
authors.forename: A
authors.initials: A
authors.lastname: Rosselet
authors.forename: D
authors.initials: D
authors.lastname: Bunjes
authors.forename: B
authors.initials: B
authors.lastname: Rio
authors.forename: M
authors.initials: M
authors.lastname: Brune
authors.forename: A
authors.initials: A
authors.lastname: Nagler
authors.forename: N C
authors.initials: NC
authors.lastname: Gorin
authors.forename: F
authors.initials: F
authors.lastname: Frassoni
authors.forename: V
authors.initials: V
authors.lastname: Rocha
mesh_terms: D000368:Aged; D005260:Female; D006680:HLA Antigens / Q000235:genetics / Q000276:immunology; D006650:Histocompatibility Testing; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000276:immunology / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D036102:Peripheral Blood Stem Cell Transplantation; D012008:Recurrence; D012189:Retrospective Studies; D035781:Siblings; D016019:Survival Analysis; D019172:Transplantation Conditioning; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous
chemical_list: D006680:HLA Antigens